- Arog Pharmaceuticals Receives FDA Orphan Drug Designation for Crenolanib for the Treatment of Gastric Cancer, Including Cancer of the Gastroesophageal Junction (October 2019)
- Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib in Relapsed or Refractory FLT3-Positive AML (December 2017)
- Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2017 American Society of Clinical Oncology Annual Meeting
- Arog Pharmaceuticals Presents Crenolanib Clinical Data at 57th American Society of Hematology Annual Meeting
- Arog Pharmaceuticals Receives Orphan Drug Designation in the European Union for Crenolanib for the Treatment of Acute Myeloid Leukemia and Soft Tissue Sarcoma (October 2016)
- AROG Pharmaceuticals to Present Clinical Data on Crenolanib at the 2016 American Society of Hematology Annual Meeting
- Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene
- Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting
